Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination
(2013) In PLoS ONE 8(6).- Abstract
Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza... (More)
Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.
(Less)
- author
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- in
- PLoS ONE
- volume
- 8
- issue
- 6
- article number
- e66125
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- scopus:84879269590
- pmid:23840413
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0066125
- project
- Newly introduced vaccines: effectiveness and determinants of acceptance
- Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
- language
- English
- LU publication?
- no
- id
- d4c7107d-465c-405f-8ee6-0710dd5b69b6
- date added to LUP
- 2020-05-14 14:24:47
- date last changed
- 2024-01-02 10:58:09
@article{d4c7107d-465c-405f-8ee6-0710dd5b69b6, abstract = {{<p>Introduction:Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness.Methods:VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%.Results:Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects.Conclusions:Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.</p>}}, author = {{Gefenaite, Giedre and Tacken, Margot and Bos, Jens and Stirbu-Wagner, Irina and Korevaar, Joke C. and Stolk, Ronald P. and Wolters, Bert and Bijl, Marc and Postma, Maarten J. and Wilschut, Jan and Nichol, Kristin L. and Hak, Eelko}}, issn = {{1932-6203}}, language = {{eng}}, number = {{6}}, publisher = {{Public Library of Science (PLoS)}}, series = {{PLoS ONE}}, title = {{Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination}}, url = {{http://dx.doi.org/10.1371/journal.pone.0066125}}, doi = {{10.1371/journal.pone.0066125}}, volume = {{8}}, year = {{2013}}, }